Holen Sie sich die Stockscreener-App
1.85
37.71%
-1.12
Handel nachbörslich:
1.90
0.05
+2.70%
Dogwood Therapeutics Inc Aktie (DWTX) Neueste Nachrichten
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study - The Manila Times
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 - GlobeNewswire
Dogwood Reports Positive Long-COVID Trial Data; Low-Dose IMC-2 Shows Promise in Fatigue Reduction | DWTX Stock News - StockTitan
Zacks Small Cap Has Negative Outlook of DWTX FY2024 Earnings - Defense World
Barclays Forecasts Strong Price Appreciation for Arista Networks (NYSE:ANET) Stock - Defense World
Dogwood Therapeutics Announces Third Quarter Financial ResultsOn November 7, 2024, Dogwood Therapeutics, Inc. (Nasdaq: DWTX) disclosed its financial performance for the third quarter ending September 30, 2024. The company, newly formed in Octob - Defense World
DWTX: Phase 2 Long COVID Results Expected Soon - Smartkarma
U.S. Stock market top losers:1847 Holdings LLC drop by 41.56%, Interactive Strength Inc. declined by 27.76% during mid day trading - Business Upturn
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
White Cliff Minerals Director Increases Shareholding - MSN
Dogwood Therapeutics Faces Potential Asset Loss and Financial Risks Amid Sealbond Repurchase Option - TipRanks
Dogwood Therapeutics Inc (DWTX) Quarterly 10-Q Report - Quartz
Dogwood Therapeutics Reports Q3 2024 Financial Results - TipRanks
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results - GlobeNewswire
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia - Marketscreener.com
Craig-Hallum Initiates Coverage of PolyPid (PYPD) with Buy Recommendation - MSN
Peregrine Gold Ltd Confirms Prospectus Lodgement for Security Issue - MSN
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - Marketscreener.com
Flutter Entertainment Files Block Listing Application for Ordinary Shares - Defense World
Nano Nuclear Energy Inc. Completes Full Exercise of Over-Allotment Option, Generating Approximately $37.7 Million in Net Proceeds - Defense World
AgEagle Aerial Systems Appoints Kevin Lowdermilk as Independent Director - Defense World
Dogwood Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
DWTXDogwood Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Dogwood Therapeutics regains Nasdaq compliance - Investing.com
Dogwood Therapeutics regains Nasdaq compliance By Investing.com - Investing.com UK
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid Fibromyalgia - Marketscreener.com
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Dogwood Therapeutics : Corporate Presentation (Virios DWTX Inc. Corporate Overview Q4 2024) - Marketscreener.com
Healthpeak Properties raised to Buy at Deutsche on leasing prospects - MSN
Dogwood Therapeutics, Inc. Expected to Earn Q3 2024 Earnings of ($1.40) Per Share (NASDAQ:DWTX) - Defense World
Dogwood Therapeutics, Inc.DWTX: Virios Therapeutics Becomes Dogwood Therapeutics - Smartkarma
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.03% - MSN
Financial Metrics Check: Dogwood Therapeutics Inc. (DWTX)’s Ratios for Trailing Twelve Months - The Dwinnex
VIRIOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Dogwood Therapeutics (DWTX) Stock Chart and Price History 2024 - MarketBeat
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 - Marketscreener.com
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Marketscreener.com
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
United States shares higher at close of trade; Dow Jones Industrial Average up 1.03% - Investing.com India
Virios Therapeutics shares target raised on Wex merger news - Investing.com
New obesity treatment has this tiny co soaring 💃 - RagingBull
Virios Therapeutics Transforms into Dogwood Therapeutics - Yahoo Finance
CKLIFE SCIENCES Hopes to Introduce Investors for Newly Merged Dogwood (DWTX.US) - AASTOCKS.com
Virios Therapeutics announces strategic merger and financing - Investing.com
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. to Combine to Form Dogwood Therapeutics, Inc. - Orrick
Virios Therapeutics And Wex Pharmaceuticals To Merge - citybiz
VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders - Marketscreener.com
Virios Therapeutics, Wex Pharmaceuticals announce business combination agreement - TipRanks
Virios, and Wex Pharmaceuticals report business combination to form Dogwood Therapeutics - MSN
Virios Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Conjoint Inc. Enters into the Loan Agreement with the Virios Therapeutics, Inc - Marketscreener.com
Virios Therapeutics announces strategic merger and financing By Investing.com - Investing.com UK
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) - Yahoo Finance
Virios Therapeutics Announces Second Quarter 2024 Financial Results - Marketscreener.com
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study - Marketscreener.com
Capital Bancorp (CBNK) to Buy Integrated Financial for $66M - Yahoo Finance
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results - Marketscreener.com
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Marketscreener.com
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):